Under construction – not a live service
Sign in
Taking peoplePhase 3

Tests baricitinib for long-term safety in children with juvenile arthritis

Tests the drug baricitinib in children with juvenile idiopathic arthritis, aged 1 to 17.

Key facts

Who runs it
Eli Lilly and Company
Where
Moscow, RussiaSee the 2 sitesAlso in 19 other countries, 75 sites
Registry title
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Status
Recruiting
Phase
Phase 3
People taking part
190 people, planned
Started
5 Apr 2019
Expected to end
Jul 2031
Type of study
Interventional
Treatments tested
  • Baricitinib
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teens with juvenile idiopathic arthritis who finished an earlier baricitinib study. It checks long-term safety and how well baricitinib works.

Age
From 1 year to under 18 years.
Sex
All sexes can join.
Disease stage
Juvenile idiopathic arthritis (JIA).
Earlier treatment
Must have completed a previous study of baricitinib for JIA.

Main reasons for not taking part

  • Baricitinib was permanently stopped in the earlier study.
  • Developed an allergy to baricitinib.

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Participants must have completed a previous study of baricitinib for the treatment of JIA

Who cannot take part

  • Participants must not have had a permanent discontinuation of baricitinib in the prior study
  • Participants must have not developed an allergy to baricitinib

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 18 years old?

Where in Russia

Also in 19 other countries, 75 sites

  • Federal State Budgetary Scientific Institution Research Institute Rheumatology named after V.A.NasonovaMoscow, RussiaNo longer taking part
  • Scientific Center of Children's HealthMoscow, RussiaNo longer taking part

About the trial

What the trial wants to find out

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

The group in the trial

  • BaricitinibTreatment being tested

    Baricitinib given orally.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Plain-language title
Tests baricitinib for long-term safety in children with juvenile arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT03773965, who can take part
Record updated
4 November 2026